BVBalance™ · Investigational Prototype · Patent Pending

A bioresorbable path to lasting vaginal microbiome balance

BVBalance™ pairs a targeted biofilm disruptor with sustained Lactobacillus delivery in a single fully bioresorbable insert — designed to break the recurrent BV cycle alongside standard oral antibiotics.

See How It Works For Providers & Researchers

Adaptive Auxetic Scaffold & Biphasic Payload Delivery

Standard antibiotics treat the infection. They don't treat why it keeps coming back.

Protective bacterial biofilms shield pathogens from oral antibiotics, driving the recurrence cycle that leaves patients and providers searching for a better answer.

30%

of women experience BV recurrence within 3 months of oral treatment

50-70%

of recurrent cases are linked to persistent vaginal biofilms

$4.8B

spent annually in the US managing recurrent BV

One insert. Three phases of action.

Select a phase to see how BVBalance™ works alongside standard care, from first insertion to full microbiome recovery.

Zero-Retrieval Profile

BVBalance™ safely bioresorbs completely over 14–30 days via PLGA degradation — no follow-up removal visit required.

How BVBalance™ Fits Into Treatment

The intended treatment sequence, from diagnosis through the antibiotic course.

BV symptoms appear
Patient seeks medical care
Patient is diagnosed with BV
Standard antibiotics and BVBalance™ are prescribed
Patient begins the oral antibiotic and inserts BVBalance™ at the same time
The antibiotic course continues while BVBalance™ stays in place
BVBalance™ bioresorbs over the course of the antibiotics
No removal visit required

Illustrative sequence. BVBalance™ is an investigational prototype not yet cleared for clinical or commercial use.

In The News

Press coverage of Solibra Health and the research behind BVBalance™.

The State Press (ASU)

April 2026

SciTech: Women-specific research solutions

Highlighting innovative research and women-focused health solutions developed at Arizona State University, featuring Solibra Health's bioresorbable therapeutic platform.

Read the Article

How BVBalance™ compares

A side-by-side look at current recurrent BV treatment options.

Swipe the table sideways to compare →

Comparison of recurrent BV treatment approaches across oral antibiotics, OTC boric acid suppositories and BVBalance.
Treatment Approach	Oral Antibiotics Alone	OTC Boric Acid Suppositories	BVBalance™
Recurrence Rate (3 months)	~30% recurrence	~20–30% recurrence	Designed for meaningfully lower recurrence*
Biofilm Disruption	Limited — biofilms shield pathogens	Partial, pH-based disruption	Targeted biofilm disruptor, used as an antibiotic adjunct
Microbiome Restoration	Not addressed	Not addressed	Sustained Lactobacillus delivery
Treatment Duration	5–7 day oral course	Nightly insertion for 2–3 weeks	Single insert, active over 14–30 days
Retrieval Required	N/A (oral)	N/A (dissolves)	None — fully bioresorbable

Growth financing

2030+

Commercial launch and revenue generation

Illustrative timeline, subject to change. BVBalance™ is an investigational prototype not yet cleared for clinical or commercial use.

Manufacturing & Quality

Three fabrication streams run in parallel, each gated by its own quality checkpoint, then converge into a single finishing line.

Parallel fabrication

Scaffold

Bioresorbable auxetic scaffold fabrication

Hydrogel

Hydrogel and chitosan preparation

Applicator

Applicator molding and finishing

Quality checkpoint on every stream

Converged finishing line

Aseptic filling
Sterilization
Packaging

Go-to-Market Strategy

Reaching women already seeking care, through the clinicians they already see and the channels they already use.

Multi-channel launch approach

OB/GYN & women's health providersThe primary channel at launch, focused on clinician education.
PharmaciesRetail and specialty pharmacy distribution, with work toward a reimbursement code.
Direct-to-consumerAn owned platform for access, education and ongoing support.
Scale utilizationWiden the clinician network and work toward integration into routine care.

Phased market entry

Phase 1 — Verification & validation

Complete preclinical and clinical validation, and generate the data behind any claim.

Phase 2 — FDA & regulatory

Finalize design and quality systems, pursue FDA clearance, and stand up compliant manufacturing.

Phase 3 — Launch

Open retail and direct-to-consumer channels alongside education and awareness work.

Planned commercial strategy. BVBalance™ is an investigational prototype not yet cleared for clinical or commercial use, and no launch timing is implied.

Provider & Clinical Trial Portal

Clinicians and research partners can track enrollment status, view study protocols, and access investigational-use materials for BVBalance™.

Request Provider Access

Meet the Team Behind Solibra Health

Balance starts with good design — and with a team that has lived the problem it is solving.

Founding Roots

Solibra Health was founded by an all-female Biomedical Engineering team spun out of Arizona State University — built from the ground up to close a long-ignored gap in women's health.

Clinical Research Network

We work in close collaboration with women's health clinicians and advisors, including institutions such as Mayo Clinic Phoenix, to ground every design decision in real clinical practice.

Our Mission

To transform gynecological health by turning women's lived experiences into trusted, science-backed solutions that break cycles of recurrence and restore biological balance.